sc 51089 has been researched along with 5,8,11,14-eicosatetraynoic acid in 1 studies
| Studies (sc 51089) | Trials (sc 51089) | Recent Studies (post-2010) (sc 51089) | Studies (5,8,11,14-eicosatetraynoic acid) | Trials (5,8,11,14-eicosatetraynoic acid) | Recent Studies (post-2010) (5,8,11,14-eicosatetraynoic acid) |
|---|---|---|---|---|---|
| 41 | 1 | 19 | 573 | 1 | 16 |
| Protein | Taxonomy | sc 51089 (IC50) | 5,8,11,14-eicosatetraynoic acid (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 1.78 | |
| Myeloid cell leukemia sequence 1 (BCL2-related) | Homo sapiens (human) | 0.4415 | |
| envelope glycoprotein | Human immunodeficiency virus 1 | 11.9 | |
| Vif | Human immunodeficiency virus 1 | 0.86 | |
| Tat | Human immunodeficiency virus 1 | 2.379 | |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | 0.86 | |
| dual specificity protein phosphatase 6 | Rattus norvegicus (Norway rat) | 21.683 | |
| tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | 17.7 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 1.78 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 1.78 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 1.78 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 1.78 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 1.78 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Craib, SJ; Ellington, HC; Pertwee, RG; Ross, RA | 1 |
1 other study(ies) available for sc 51089 and 5,8,11,14-eicosatetraynoic acid
| Article | Year |
|---|---|
A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Arachidonic Acids; Bronchi; Calcium Channel Blockers; Capsaicin; Cyclohexanols; Dose-Response Relationship, Drug; Endocannabinoids; Fatty Acids, Unsaturated; Guinea Pigs; Hydrazines; In Vitro Techniques; Indomethacin; Lipoxygenase; Muscle Contraction; Oxazepines; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Drug; Rimonabant; Thiorphan | 2001 |